Cell therapy
LVIVO-TaVec400 is a product given as a single-dose intravenous infusion. It is studied in relapsed or refractory systemic lupus erythematosus, relapsed or refractory IgG4-related disease, progressive multiple sclerosis, and relapsed or refractory myasthenia gravis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07583030 | Early Phase 1 | Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) | Withdrawn | LEGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Progressive Multiple Sclerosis (PMS)Relapsed/Refractory IgG4-Related Disease (r/r IgG4-RD)Relapsed/Refractory Myasthenia Gravis(r/r MS)Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE)